{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:52:04Z","timestamp":1776408724072,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the special fund of the National Clinical Key Specialty Construction Program","award":["P. R. China (2023)"],"award-info":[{"award-number":["P. R. China (2023)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06952-y","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:11:18Z","timestamp":1774253478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of monocyte percentage and extranodal involvement in classical hodgkin lymphoma: A multicenter real-world study of 547 chinese patients"],"prefix":"10.1007","volume":"105","author":[{"given":"Lingli","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinping","family":"Pi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiefei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaili","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hebing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingtong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuozi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"12","key":"6952_CR1","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/ajh.27470","volume":"99","author":"SM Ansell","year":"2024","unstructured":"Ansell SM (2024) Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol 99(12):2367\u20132378","journal-title":"Am J Hematol"},{"issue":"11","key":"6952_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1182\/blood.2022018076","volume":"141","author":"LC Fox","year":"2023","unstructured":"Fox LC (2023) Unraveling family ties in Hodgkin lymphoma. Blood 141(11):1240\u20131241","journal-title":"Blood"},{"issue":"1","key":"6952_CR3","doi-asserted-by":"publisher","first-page":"e70017","DOI":"10.1002\/hon.70017","volume":"43","author":"P Zhao","year":"2025","unstructured":"Zhao P, Zhao S, Huang C, Li Y, Wang J, Xu J et al (2025) Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study. Hematol Oncol 43(1):e70017","journal-title":"Hematol Oncol"},{"issue":"10310","key":"6952_CR4","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","volume":"398","author":"P Brice","year":"2021","unstructured":"Brice P, de Kerviler E, Friedberg JW (2021) Classical Hodgkin lymphoma. Lancet 398(10310):1518\u20131527","journal-title":"Lancet"},{"issue":"4","key":"6952_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.molmed.2024.10.004","volume":"31","author":"R K\u00fcppers","year":"2025","unstructured":"K\u00fcppers R (2025) Advances in Hodgkin lymphoma research. Trends Mol Med 31(4):326\u2013343","journal-title":"Trends Mol Med"},{"issue":"17","key":"6952_CR6","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med 372(17):1598\u20131607","journal-title":"N Engl J Med"},{"issue":"4","key":"6952_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","volume":"387","author":"SM Ansell","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM, D\u0142ugosz-Danecka M, Kim WS, Gallamini A et al (2022) Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma. N Engl J Med 387(4):310\u2013320","journal-title":"N Engl J Med"},{"issue":"1","key":"6952_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.23.01177","volume":"42","author":"S Luminari","year":"2024","unstructured":"Luminari S, Fossa A, Trotman J, Molin D, d\u2019Amore F, Enblad G et al (2024) Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. J Clin Oncol 42(1):13\u201318","journal-title":"J Clin Oncol"},{"issue":"3","key":"6952_CR9","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6952_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","volume":"15","author":"J Huang","year":"2022","unstructured":"Huang J, Pang WS, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W et al (2022) Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol 15(1):57","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6952_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","volume":"13","author":"N Zhang","year":"2023","unstructured":"Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G et al (2023) Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J 13(1):82","journal-title":"Blood Cancer J"},{"key":"6952_CR12","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2147\/CMAR.S363235","volume":"14","author":"S \u00c7okgezer","year":"2022","unstructured":"\u00c7okgezer S, Elverdi T, Saliho\u011flu A, Ar MC, \u00d6ng\u00f6ren \u015e, Ba\u015flar Z et al (2022) Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged\u2009\u2265\u200950 Years: A Single-Center Experience Over Two Decades. Cancer Manag Res 14:1911\u20131921","journal-title":"Cancer Manag Res"},{"key":"6952_CR13","doi-asserted-by":"crossref","unstructured":"Pavlovi\u0107 A, Miljak A, Brzica K, Glavina Durdov M (2024) The Abundance of FOXP3, FOXP3\/CD4 and CD8 Cells in the Microenvironment of Nodular Sclerosis and Mixed Cellularity Subtypes Is Associated with the Epstein-Barr Virus Status of Classic Hodgkin Lymphoma. Biomedicines. ;12(8):1680","DOI":"10.3390\/biomedicines12081680"},{"issue":"6","key":"6952_CR14","doi-asserted-by":"publisher","first-page":"e055524","DOI":"10.1136\/bmjopen-2021-055524","volume":"12","author":"X Liang","year":"2022","unstructured":"Liang X, Zhang M, Zhang Z, Tan S, Li Y, Zhong Y et al (2022) Nomogram model and risk score predicting overall survival and guiding clinical decision in patients with Hodgkin\u2019s lymphoma: an observational study using SEER population-based data. BMJ Open 12(6):e055524","journal-title":"BMJ Open"},{"issue":"1","key":"6952_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1182\/asheducation-2003.1.225","volume":"2003","author":"V Diehl","year":"2003","unstructured":"Diehl V, Stein H, Hummel M, Zollinger R, Connors JM (2003) Hodgkin\u2019s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease. Hematology 2003(1):225\u2013247","journal-title":"Hematology"},{"issue":"3","key":"6952_CR16","first-page":"e35922","volume":"15","author":"RH Alelyani","year":"2023","unstructured":"Alelyani RH, Alghamdi AH, Almughamisi TA, Alshareef AM, Kadasa AN, Alrajhi AM et al (2023) Incidence and Risk Factors of Infections Among Diffuse Large B-cell Lymphoma and Classical Hodgkin\u2019s Lymphoma Patients in a Tertiary Care Center in Saudi Arabia: A Retrospective Cohort Study. Cureus 15(3):e35922","journal-title":"Cureus"},{"issue":"11","key":"6952_CR17","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1200\/JCO.22.02473","volume":"41","author":"AM Rodday","year":"2023","unstructured":"Rodday AM, Parsons SK, Upshaw JN, Friedberg JW, Gallamini A, Hawkes E et al (2023) The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. J Clin Oncol 41(11):2076\u20132086","journal-title":"J Clin Oncol"},{"issue":"1","key":"6952_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-024-03108-6","volume":"43","author":"J Velasco-Suelto","year":"2024","unstructured":"Velasco-Suelto J, G\u00e1lvez-Carvajal L, Comino-M\u00e9ndez I, Rueda-Dom\u00ednguez A (2024) Hodgkin lymphoma and liquid biopsy: a story to be told. J Exp Clin Cancer Res 43(1):184","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"6952_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/ijlh.14379","volume":"47","author":"P Patir","year":"2025","unstructured":"Patir P, Cerci K, Kurtoglu E (2025) Prognostic Evaluation of Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and Hematological Indices in Classic Hodgkin Lymphoma. Int J Lab Hematol 47(1):68\u201378","journal-title":"Int J Lab Hematol"},{"issue":"14","key":"6952_CR20","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1080\/10428194.2024.2395458","volume":"65","author":"\u00d6 Mehtap","year":"2024","unstructured":"Mehtap \u00d6, Toptas T, Dal MS, Karadag FK, Atas U, \u00d6zsan GH et al (2024) A new scoring system to predict survival in elderly advanced stage Hodgkin lymphoma patients. Leuk Lymphoma 65(14):2190\u20132198","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"6952_CR21","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1136\/bjo-2022-321656","volume":"107","author":"J Shi","year":"2023","unstructured":"Shi J, Zhu T, Zhou M, Zhou X, Song X, Wang Y et al (2023) Predicting the risk of distant and local recurrence for patients with ocular adnexal extranodal marginal zone lymphoma: a matched case-control study. Br J Ophthalmol 107(10):1560\u20131566","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"6952_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40364-024-00605-w","volume":"12","author":"L Dai","year":"2024","unstructured":"Dai L, Fan G, Xie T, Li L, Tang L, Chen H et al (2024) Single-cell and spatial transcriptomics reveal a high glycolysis B cell and tumor-associated macrophages cluster correlated with poor prognosis and exhausted immune microenvironment in diffuse large B-cell lymphoma. Biomark Res 12(1):58","journal-title":"Biomark Res"},{"key":"6952_CR23","doi-asserted-by":"publisher","first-page":"109235","DOI":"10.1016\/j.intimp.2022.109235","volume":"112","author":"X Xiong","year":"2022","unstructured":"Xiong X, Xie X, Wang Z, Zhang Y, Wang L (2022) Tumor-associated macrophages in lymphoma: From mechanisms to therapy. Int Immunopharmacol 112:109235","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"6952_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s43556-023-00141-3","volume":"4","author":"H Yang","year":"2023","unstructured":"Yang H, Xun Y, Ke C, Tateishi K, You H (2023) Extranodal lymphoma: pathogenesis, diagnosis and treatment. Mol Biomed 4(1):29","journal-title":"Mol Biomed"},{"issue":"21","key":"6952_CR25","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1182\/bloodadvances.2024013743","volume":"8","author":"N Epperla","year":"2024","unstructured":"Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T et al (2024) Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Adv 8(21):5458\u20135466","journal-title":"Blood Adv"},{"issue":"18","key":"6952_CR26","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1002\/cncr.34375","volume":"128","author":"Z Lu","year":"2022","unstructured":"Lu Z, Teng Y, Ning X, Wang H, Feng W, Ou C (2022) Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors. Cancer 128(18):3330\u20133339","journal-title":"Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06952-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06952-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06952-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:00:00Z","timestamp":1776405600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06952-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6952"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06952-y","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"195"}}